Business Wire

ACTILITY

12.7.2016 18:36:11 CEST | Business Wire | Press release

Share
Actility’s ThingPark Powers World’s First LoRA Internet of Things Network

Actility, the industry leader in low power wide area networking, is proud to celebrate the successful deployment of the world’s first nationwide LoRa network for the Internet of Things with Dutch telecom operator KPN. After an intense period of 8 months’ work, several hundred LoRa antennas have been installed all over the Netherlands. KPN’s LoRa project initially went live in the cities of Rotterdam and The Hague. Thanks to strong positive feedback and consumer interest in the early deployments, the network roll-out was accelerated at the beginning of this year, and has just been completed. The KPN network will support uses as varied as street lighting, street signage, waste management and animal tracking.

Actility and KPN have been pioneering the world-leading development of the European Internet of Things together since 2014. Combining Actility’s innovative ThingPark solution for the Internet of Things with KPN’s leading mobile network gives the country a world #1 “best-in-class” solution. It will address the needs of a wide variety of markets with very different requirements, but sharing the common need to connect sensors cost-effectively, over long distances and in both built-up areas and wide open countryside. KPN will leverage the ThingPark Wireless solution to connect a wide range of objects in markets as diverse as agriculture, smart building, transport infrastructure and healthcare applications.

One of the most attractive applications of KPN’s LoRa network is Smart Public Space Management. Citizens across the Netherlands will see a variety of benefits including improved street signage, better waste management in public spaces and smart street lighting.

“We congratulate KPN on being first in the world, thanks to their extremely efficient and successful roll-out across the Netherlands. KPN is a true pioneer and has made good on its ambition to turn the whole country into a smart nation, connecting cities and rural areas, and making life a little smarter for all its inhabitants”, says Actility’s CEO Mike Mulica.

“KPN is pleased with the fruitful collaboration with Actility, which allowed the successful nationwide roll-out in less than a year”, says Jacob Groote, Executive Vice President Service Platforms at KPN.

About Actility

Actility is an innovator and industry leader in LPWA (Low Power Wide Area) large scale infrastructure. Actility’s ThingPark™ is a next generation standards-based IoT platform. The ThingPark Wireless LPWA network provides long-range coverage for low-power consumption sensors. ThingPark Mash-up offers big data storage for sensor data and exposes sensor capabilities through an open API, enabling developers to create vertical applications using the installed base of sensors. The ThingPark platform offers embedded software solutions and cloud solutions to connect devices with innovative applications. With its dedicated online marketplace for IoT sensors, applications and network solutions, ThingPark simplifies and accelerates the roll-out of innovative IoT services. Actility is a founding member of the LoRa Alliance: the largest, most powerful open standards-based enabler of the Internet of Things. To find out more, visit www.thingpark.com .

About KPN: to learn more visit www.kpn.com

Contact:

Actility
Anne van Gemert
anne.vangemert@actility.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye